Clinical evolution

Icon boosts bioanalytical presence through Prevalere buy

Icon boosts bioanalytical presence through Prevalere buy

By Gareth Macdonald

Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...

eClinical potential explored

eClinical potential explored

By Kirsty Barnes

As eClinical gathers momentum, Outsourcing-Pharma.com spoke to two
contract research organisations (CROs), Icon and Parexel, to get
their views on the present and future of these emerging
technologies.